Evotec SE

EVT: XETR (DEU)

Morningstar Rating for Stocks	Fair Value	Economic Moat	Capital Allocation
	LOCK\|NJ$YsX	LOCK\|%&D	LOCK\|&H<%B>D

Evotec Earnings: Biologics Strength Anchors 2024 as No-Moat Firm Sharpens Strategic Focus

Rachel Elfman ,

Apr 17, 2025

No-moat Evotec reported solid fourth-quarter and full-year 2024 results that aligned with our expectations. Our EUR 8.50 per share fair value estimate is intact, and we revised our USD estimate to $4.82 to reflect the current exchange rate. Full-year revenue increased 2% to EUR 797 million, driven by an impressive 71% growth in the Just-Evotec Biologics segment. However, this was offset by a 9% decline in shared R&D, which remained under pressure due to ongoing weakness in pharma and biotech research and development spending.

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

United States

Evotec SE

Evotec Earnings: Biologics Strength Anchors 2024 as No-Moat Firm Sharpens Strategic Focus

Company Report Archive

Sponsor Center

What We Do

Company

Get Help